REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Sermorelin Sleep Protocol

GH Optimizationbeginner

82

synergy

82
Share
Peptides

2

Avg Daily mcg

300

Level

beginner

Added

May 17, 2026

Overview

The Sermorelin Sleep Protocol leverages the natural relationship between growth hormone secretion and sleep architecture to enhance both simultaneously. Approximately 70% of daily GH secretion occurs during slow-wave (deep) sleep, and conversely, adequate GH signaling promotes deeper and more restorative sleep stages. Sermorelin is a 29-amino-acid GHRH analog that is identical to the first 29 amino acids of endogenous GHRH. It has a long clinical history, having been FDA-approved in the 1990s for pediatric GH deficiency, and remains Category 1 — legal for compounding pharmacies to produce. When administered 30 minutes before bed on an empty stomach, Sermorelin amplifies the natural nocturnal GH surge that occurs approximately 60-90 minutes after sleep onset. This enhanced GH pulse deepens slow-wave sleep, which in turn promotes further GH release — creating a positive feedback loop. Low-dose Ipamorelin (100mcg) is added to amplify this pulse via ghrelin-receptor co-activation without doses high enough to cause any sleep-disrupting appetite signaling. The protocol is classified as beginner-friendly because Sermorelin has decades of clinical safety data, the doses are conservative, and the timing aligns with natural physiology rather than fighting it. Users typically report improvements in sleep quality within the first week, with deeper, less interrupted sleep and more vivid dreaming (indicating enhanced REM cycling). Over 4-8 weeks, the cumulative effect of improved nightly GH secretion manifests as better recovery, improved skin texture, modest fat reduction, and increased morning energy. This is an excellent entry point for individuals new to peptide therapy who want meaningful benefits with minimal complexity.

Dosing Protocol

Sermorelin

nightly· subcutaneous

Read more about Sermorelin →

200 mcg

per dose

Ipamorelin

nightly· subcutaneous

Read more about Ipamorelin →

100 mcg

per dose

Goals & Evidence

Deep sleepGH pulseRecoveryAnti-agingREM sleep
Evidence tier:Human RCT

Warnings

  • Sermorelin is Cat 1 (legal to compound). Ipamorelin is Cat 2. Administer 30 min before bed on empty stomach.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.